Stock Scorecard



Stock Summary for ProQR Therapeutics N.V (PRQR) - $1.40 as of 3/31/2025 2:22:27 PM EST

Total Score

13 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PRQR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PRQR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PRQR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PRQR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PRQR (22 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PRQR

ProQR Announces Year End 2024 Operating and Financial Results - ProQR Therapeutics ( NASDAQ:PRQR ) 3/13/2025 11:00:00 AM
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Blaize Holdings ( NASDAQ:BZAI ) , Maplebear ( NASDAQ:CART ) 2/12/2025 1:53:00 PM
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - NVIDIA ( NASDAQ:NVDA ) 11/18/2024 3:12:00 PM
This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - First Solar ( NASDAQ:FSLR ) 10/29/2024 1:50:00 PM
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - CSX ( NASDAQ:CSX ) 10/17/2024 1:15:00 PM
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Taiwan Semiconductor ( NYSE:TSM ) 10/17/2024 9:39:00 AM
Best Momentum Stocks to Buy for October 2nd 10/2/2024 2:15:00 PM
ProQR Announces Year End 2023 Operating and Financial Results - ProQR Therapeutics ( NASDAQ:PRQR ) 3/13/2024 11:00:00 AM
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing - ProQR Therapeutics ( NASDAQ:PRQR ) 2/15/2024 12:00:00 PM
Is ProQR ( PRQR ) Stock a Solid Choice Right Now? 12/28/2023 1:44:00 PM

Financial Details for PRQR

Company Overview

Ticker PRQR
Company Name ProQR Therapeutics N.V
Country USA
Description ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is headquartered in Leiden, the Netherlands.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/22/2025

Stock Price History

Last Day Price 1.40
Price 4 Years Ago 8.01
Last Day Price Updated 3/31/2025 2:22:27 PM EST
Last Day Volume 323,303
Average Daily Volume 573,294
52-Week High 4.62
52-Week Low 1.43
Last Price to 52 Week Low 2.10%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -6.29
Free Cash Flow Ratio 0.99
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 3.95
Total Cash Per Share 1.42
Book Value Per Share Most Recent Quarter 0.84
Price to Book Ratio 1.67
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 8.18
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 105,213,000
Market Capitalization 147,298,200
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 1.27%
Reported EPS 12 Trailing Months -0.35
Reported EPS Past Year -0.30
Reported EPS Prior Year -0.35
Net Income Twelve Trailing Months -27,808,078
Net Income Past Year -27,763,000
Net Income Prior Year -28,119,000
Quarterly Revenue Growth YOY 35.30%
5-Year Revenue Growth 57.79%
Operating Margin Twelve Trailing Months -226.90%

Balance Sheet

Total Cash Most Recent Quarter 149,408,000
Total Cash Past Year 149,408,000
Total Cash Prior Year 118,925,000
Net Cash Position Most Recent Quarter 145,116,000
Net Cash Position Past Year 145,116,000
Long Term Debt Past Year 4,292,000
Long Term Debt Prior Year 4,292,000
Total Debt Most Recent Quarter 4,292,000
Equity to Debt Ratio Past Year 0.95
Equity to Debt Ratio Most Recent Quarter 0.95
Total Stockholder Equity Past Year 88,560,000
Total Stockholder Equity Prior Year 41,390,000
Total Stockholder Equity Most Recent Quarter 88,560,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -37,899,708
Free Cash Flow Per Share Twelve Trailing Months -0.36
Free Cash Flow Past Year -37,811,000
Free Cash Flow Prior Year 20,177,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.19
MACD Signal -0.17
20-Day Bollinger Lower Band 1.18
20-Day Bollinger Middle Band 2.56
20-Day Bollinger Upper Band 3.93
Beta 0.24
RSI 24.36
50-Day SMA 2.33
150-Day SMA 1.91
200-Day SMA 2.77

System

Modified 3/28/2025 5:16:15 AM EST